Literature DB >> 32078830

Endothelial dysfunction and arterial stiffness in patients with systemic lupus erythematosus: A systematic review and meta-analysis.

Claudia Mendoza-Pinto1, Adriana Rojas-Villarraga2, Nicolás Molano-González3, Mario García-Carrasco4, Pamela Munguía-Realpozo1, Ivet Etchegaray-Morales5, Héctor Morales-Sánchez5, Roberto Berra-Romani6, Ricard Cervera7.   

Abstract

BACKGROUND AND AIMS: Non-invasive surrogates of cardiovascular (CV) disease such as endothelial dysfunction (ED) and peripheral arterial stiffness (AS) have been evaluated in systemic lupus erythematosus (SLE) patients. The aim of this study was to systematically review and meta-analyze reports of cardiovascular disease (CVD) in SLE patients, as measured by ED and AS.
METHODS: Studies analyzing the relationship of SLE with ED (flow-mediated dilatation [FMD], nitroglycerin-mediated dilatation [NMD] and peripheral arterial tonometry [PAT]) and AS (augmentation index [AIx], pulse wave velocity [PWV]) were systematically searched for in PubMed, Cochrane library, EMBASE, VHL, SciELO and Web of Science databases. Inclusion criteria included peer-review and English language. Mean differences (MD) and 95% confidence intervals (CIs) were estimated using the random effect model. The study was registered with PROSPERO, number CRD42019121068.
RESULTS: The meta-analysis included 49 studies. FMD data from 18 studies including 943 SLE subjects (mean age = 38.71 [95%CI 36.21, 41.21] years) and 644 unaffected controls (mean age = 38.63 [95%CI 36.11, 41.15] years) were included. When compared with unaffected controls, FMD in SLE subjects was decreased by 4.3% (95%CI: -6.13%, -2.47%): p < 0.001). However, NMD did not significantly differ between SLE patients and controls (MD = - 2.68%; 95% CI -6.00, 0.62; p = 0.11). A significantly increased AS between SLE patients and controls according to overall PWV (MD = 1.12 m/s; 95% CI 0.72-1.52; p < 0.001) was observed, but not for the brachial-ankle PWV. AIx was also increased in SLE patients compared with healthy controls (MD = 4.55%; 95% CI 1.48-7.63; p = 0.003).
CONCLUSIONS: Overall, SLE patients showed impaired FMD, an independent predictor of CV events. There was a higher degree of AS in SLE patients compared with controls. ED and AS in SLE should be considered when planning preventive strategies and therapies.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Arterial stiffness; Cardiovascular risk; Endothelial dysfunction; Systemic lupus erythematosus

Mesh:

Year:  2020        PMID: 32078830     DOI: 10.1016/j.atherosclerosis.2020.01.028

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

Review 1.  Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus.

Authors:  Christopher B Oliveira; Mariana J Kaplan
Journal:  Semin Immunopathol       Date:  2022-03-30       Impact factor: 11.759

Review 2.  Novel Surrogate Markers of Cardiovascular Risk in the Setting of Autoimmune Rheumatic Diseases: Current Data and Implications for the Future.

Authors:  Anna Mandel; Andreas Schwarting; Lorenzo Cavagna; Konstantinos Triantafyllias
Journal:  Front Med (Lausanne)       Date:  2022-06-30

Review 3.  Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention.

Authors:  Allison B Reiss; Benna Jacob; Saba Ahmed; Steven E Carsons; Joshua DeLeon
Journal:  Inflammation       Date:  2021-04-05       Impact factor: 4.092

4.  Do individuals with autoimmune disease have increased risk of subclinical carotid atherosclerosis and stiffness?

Authors:  Maria Del Mar Vila; Beatriz Remeseiro; Laura Igual; Roberto Elosua; Rafel Ramos; Jose Manuel Valdivielso; Ruth Martí-Lluch; Jaume Marrugat; Maria Grau
Journal:  Hypertens Res       Date:  2021-04-08       Impact factor: 3.872

5.  Assessment of vascular stiffness using different modalities in patients with systemic lupus erythematosus: a case control study.

Authors:  Waleed Ammar; Moataz Taha; Essam Baligh; Dina Osama
Journal:  Egypt Heart J       Date:  2020-05-18

Review 6.  Inflammaging as a link between autoimmunity and cardiovascular disease: the case of rheumatoid arthritis.

Authors:  Pedro Santos-Moreno; Gabriel Burgos-Angulo; Maria Alejandra Martinez-Ceballos; Alejandro Pizano; Dario Echeverri; Paula K Bautista-Niño; Anton J M Roks; Adriana Rojas-Villarraga
Journal:  RMD Open       Date:  2021-01

7.  Arterial stiffness and atherosclerosis in systemic lupus erythematosus patients.

Authors:  Hanna Dziedzic-Oleksy; Adam Mazurek; Kamil Bugała; Carlo Perricone; Leszek Drabik; Wojciech Płazak
Journal:  Reumatologia       Date:  2022-07-13

8.  Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.

Authors:  Sarfaraz A Hasni; Sarthak Gupta; Michael Davis; Elaine Poncio; Yenealem Temesgen-Oyelakin; Philip M Carlucci; Xinghao Wang; Mohammad Naqi; Martin P Playford; Rishi R Goel; Xiaobai Li; Ann J Biehl; Isabel Ochoa-Navas; Zerai Manna; Yinghui Shi; Donald Thomas; Jinguo Chen; Angélique Biancotto; Richard Apps; Foo Cheung; Yuri Kotliarov; Ashley L Babyak; Huizhi Zhou; Rongye Shi; Katie Stagliano; Wanxia Li Tsai; Laura Vian; Nathalia Gazaniga; Valentina Giudice; Shajia Lu; Stephen R Brooks; Meggan MacKay; Peter Gregersen; Nehal N Mehta; Alan T Remaley; Betty Diamond; John J O'Shea; Massimo Gadina; Mariana J Kaplan
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.